Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ballantyne

Showing results (661-670 of 999) with videos related to

Pageof 100
Sort By:
JACC. Cardiovascular Imaging|September 22, 2014
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURNRishi Puri, Steven E Nissen, Mingyuan Shao, et al.
JAMA Internal Medicine|June 8, 2026
Structured Telehealth Community Health Worker-Clinician Feedback and Diabetes Outcomes: A Randomized Clinical TrialElizabeth M Vaughan, Xiaoying Yu, Amber B Amspoker, et al.
JACC. Advances|December 4, 2025
GOULD EDU: Cluster-Randomized Trial of an Educational Intervention to Improve Lipid-Lowering Guideline AdherenceChristopher P Cannon, Christie M Ballantyne, Deepak L Bhatt, et al.
Journal of Clinical Lipidology|May 13, 2025
Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive CardiologySeyedmohammad Saadatagah, Miriam Larouche, Mohammadreza Naderian, et al.
Diabetes|October 22, 2008
Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults: the Atherosclerosis Risk in Communities studyYu Yan, Kari E North, Christie M Ballantyne, et al.
The American Journal of Cardiology|October 24, 2007
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemiaEvan A Stein, John Amerena, Christie M Ballantyne, et al.
The American Journal of Cardiology|June 23, 2009
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)Jennifer G Robinson, Christie M Ballantyne, Scott M Grundy, et al.
Cardiovascular Drugs and Therapy|February 22, 2012
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studiesStephen J Nicholls, Allan Gordon, Jan Johannson, et al.
Circulation. Cardiovascular Genetics|November 8, 2011
Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) studyPamela L Lutsey, Laura J Rasmussen-Torvik, James S Pankow, et al.
Plos One|September 10, 2014
Low-density lipoprotein electronegativity is a novel cardiometabolic risk factorJing-Fang Hsu, Tzu-Chieh Chou, Jonathan Lu, et al.
Pageof 100

Showing results (661-670 of 999) with videos related to

Sort By:
Pageof 100
JACC. Cardiovascular Imaging|September 22, 2014
Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURNRishi Puri, Steven E Nissen, Mingyuan Shao, et al.
JAMA Internal Medicine|June 8, 2026
Structured Telehealth Community Health Worker-Clinician Feedback and Diabetes Outcomes: A Randomized Clinical TrialElizabeth M Vaughan, Xiaoying Yu, Amber B Amspoker, et al.
JACC. Advances|December 4, 2025
GOULD EDU: Cluster-Randomized Trial of an Educational Intervention to Improve Lipid-Lowering Guideline AdherenceChristopher P Cannon, Christie M Ballantyne, Deepak L Bhatt, et al.
Journal of Clinical Lipidology|May 13, 2025
Recognition and management of persistent chylomicronemia: A joint expert clinical consensus by the National Lipid Association and the American Society for Preventive CardiologySeyedmohammad Saadatagah, Miriam Larouche, Mohammadreza Naderian, et al.
Diabetes|October 22, 2008
Transcription factor 7-like 2 (TCF7L2) polymorphism and context-specific risk of type 2 diabetes in African American and Caucasian adults: the Atherosclerosis Risk in Communities studyYu Yan, Kari E North, Christie M Ballantyne, et al.
The American Journal of Cardiology|October 24, 2007
Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemiaEvan A Stein, John Amerena, Christie M Ballantyne, et al.
The American Journal of Cardiology|June 23, 2009
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)Jennifer G Robinson, Christie M Ballantyne, Scott M Grundy, et al.
Cardiovascular Drugs and Therapy|February 22, 2012
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studiesStephen J Nicholls, Allan Gordon, Jan Johannson, et al.
Circulation. Cardiovascular Genetics|November 8, 2011
Relation of lipid gene scores to longitudinal trends in lipid levels and incidence of abnormal lipid levels among individuals of European ancestry: the Atherosclerosis Risk in Communities (ARIC) studyPamela L Lutsey, Laura J Rasmussen-Torvik, James S Pankow, et al.
Plos One|September 10, 2014
Low-density lipoprotein electronegativity is a novel cardiometabolic risk factorJing-Fang Hsu, Tzu-Chieh Chou, Jonathan Lu, et al.
Pageof 100